Phase 1 Psoriasis Trial, Recruiting NCT05725876 Sponsor: University Medical Center Groningen Condition: Psoriasis
Back to Psoriasis

Phase 1 Psoriasis Trial, Recruiting

NCT05725876
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Crohn's disease (CD) or plaque psoriasis (PsO)
  • People whose condition has not responded well to standard treatments
  • People with currently active disease — for Crohn's disease, this means moderate or higher disease activity based on recognised scoring tools, or a stool test result above a certain level (faecal calprotectin above 200 ug/g); for psoriasis, this means a skin severity score of 10 or higher (PASI ≥ 10), or active disease confirmed by a dermatologist
  • People aged 18 years or older
  • People who are willing and able to provide written consent to participate

Who may not be able to join:

  • People whose medical or psychiatric conditions affect their ability to give informed consent, as determined by their treating doctor
  • People who have received the medication ustekinumab within the past 15 weeks (exceptions may apply for certain groups within the trial — confirm with trial site)
  • People for whom ustekinumab is medically unsuitable or contraindicated
  • People who are currently pregnant or breastfeeding; women who could become pregnant will need to provide a negative pregnancy test result before joining

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +31503612620

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
6 January 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Quantification of fluorescent signal of fluorescent ustekinumab in CD and psoriasis patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov